BridgeBio initiated with an Outperform at Scotiabank

Scotiabank initiated coverage of BridgeBio with an Outperform rating and $44 price target he approval of BridgeBio’s transthyretin stabilizer, acoramidis, in transthyretin amyloidosis cardiomyopathy is on the horizon, with an FDA action date of November 29, the analyst tells investors in a research note. The firm thinks acoramidis will see meaningful uptake in patients that continue to progress on Pfizer’s tafamidis.